CT引导下植入125I粒子治疗非小细胞肺癌切除术后局部复发的疗效

CT-guided percutaneous interstitial implantation of 125I for recurrent patients of postoperative non-small cell lung carcinoma

    摘要
  • 摘要:
    目的 探讨CT引导下经皮穿刺植入125I粒子近距离内照射治疗非小细胞肺癌（NSCLC）切除术后局部复发的近期效果。
    方法 术前活检证实为NSCLC、术后局部复发的患者32例，处方剂量为90 Gy，通过CT引导经皮穿刺植入125I粒子。在治疗前和治疗后6个月，根据CT检查比较肿瘤体积，按国际标准判定疗效。中位随访24个月（6~72个月）。
    结果 植入粒子后，瘤体接受的平均照射剂量为153.7 Gy，D90为93.5 Gy。6个月后，完全缓解率+部分缓解率为90.6%，未发生与治疗相关的严重并发症。1年和2年的生存率分别为87%和73%，中位生存期为35个月。
    结论 在CT引导下，125I粒子植入治疗NSCLC术后局部复发安全、微创且有效。

     

    Abstract:
    Objective To evaluate the efficacy of percutaneous interstitial implantation with 125I seeds for recurrent patients of postoperative non-small cell lung carcinoma(NSCLC)guided by CT.
    Methods Thirty-two NLCLC patients were verified by biopsy pathology.Prescribed dose was 90 Gy.The percutaneous interstitial implantation of 125I seeds treatment was guided by CT.The carcinoma were scanned by CT and compared before and 6 months after treatment.Then judge the curative effect accerding to the curative standard put forward by World Health Organization.All the patients were folluwed-up for 6 to 72 months, mean 24 months.
    Results The mean radioactive dose of therapy group was 153.7 Gy, D90was 93.5 Gy.Among the 32 follow-up cases, the complete and partial remission rate was 90.6%, and no major complications.One and two year survival rate were 87%and 73%, mean survival was 35 months.
    Conclusion Percutaneous interstitial implantation with 125I seeds for recurrent patients of postoperative NSCLC guided by CT is a valid, minimally invasive and efficient method.

     

    • HTML全文
    • 参考文献(23)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回